{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:30:45Z","timestamp":1761183045563,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jiac.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T02:18:00Z","timestamp":1558664280000},"page":"780-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic-pharmacodynamic comparison of ceftriaxone regimens in acute cholangitis"],"prefix":"10.1016","volume":"25","author":[{"given":"Masao","family":"Toki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Gondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.04.006_bib1","first-page":"1297","article-title":"Acute cholangitis","volume":"70","author":"Lipsett","year":"1990","journal-title":"Surg Clin"},{"key":"10.1016\/j.jiac.2019.04.006_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00534-006-1156-7","article-title":"Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines","volume":"14","author":"Wada","year":"2007","journal-title":"J\u00a0Hepato-Biliary-Pancreatic Surg"},{"key":"10.1016\/j.jiac.2019.04.006_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00534-006-1157-6","article-title":"Antimicrobial therapy for acute cholangitis: Tokyo Guidelines","volume":"14","author":"Tanaka","year":"2007","journal-title":"J\u00a0Hepatobiliary Pancreatic Surg"},{"key":"10.1016\/j.jiac.2019.04.006_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jhbp.509","article-title":"Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis","volume":"25","author":"Miura","year":"2018","journal-title":"J\u00a0Hepatobiliary Pancreatic Sci"},{"key":"10.1016\/j.jiac.2019.04.006_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jhbp.518","article-title":"Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis","volume":"25","author":"Gomi","year":"2018","journal-title":"J\u00a0Hepatobiliary Pancreatic Sci"},{"key":"10.1016\/j.jiac.2019.04.006_bib6","first-page":"5","article-title":"Ceftriaxone versus Levofloxacin for antibiotic therapy in patients with acute cholangitis","volume":"41","author":"Kiesslich","year":"2003","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jiac.2019.04.006_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jhbp.512","article-title":"Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos)","volume":"25","author":"Kiriyama","year":"2018","journal-title":"J\u00a0Hepatobiliary Pancreatic Sci"},{"key":"10.1016\/j.jiac.2019.04.006_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00534-012-0561-3","article-title":"TG13 guidelines for diagnosis and severity gradding of acute cholangitis(with videos)","volume":"20","author":"Kiriyama","year":"2013","journal-title":"J\u00a0Hepato-Biliary-Pancreatic Sci"},{"key":"10.1016\/j.jiac.2019.04.006_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2019.04.006_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1248\/yakushi.129.821","article-title":"Personalized optimization of beta-lactam regimens based on studies of the pharmacokinetics-pharmacodynamics at the target sites","volume":"129","author":"Ikawa","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jiac.2019.04.006_bib11","first-page":"1415","article-title":"The aspects of the once a day therapy of the \u03b2-lactam antibiotics mainly in ceftriaxone","volume":"26","author":"Chikara","year":"2010","journal-title":"Antibiot Chemother"},{"key":"10.1016\/j.jiac.2019.04.006_bib12","first-page":"687","article-title":"Criteria for adverse reactions and abnormal laboratory findings in clinical trial under investigation of antibacterial agents","volume":"39","author":"Japanese Society of Chemotherapy","year":"1991","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2019.04.006_bib13","first-page":"3","article-title":"Guideline for clinical evaluation of antimicrobial drugs","volume":"66","author":"Japanese Society of Chemotherapy","year":"2018","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.04.006_bib14","first-page":"1988","article-title":"Bacteriological, pharmacokinetic and clinical evaluations of ceftriaxone in the pediatric field. Pediatric study group of ceftriaxone","volume":"39","author":"Fujii","year":"1986","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2019.04.006_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.19.3.414","article-title":"Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin","volume":"19","author":"Neu","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.04.006_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/AAC.22.5.816","article-title":"Jr. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults","volume":"22","author":"Pollock","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.04.006_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/AAC.20.2.159","article-title":"In\u00a0vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin","volume":"20","author":"Beskid","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.04.006_bib18","first-page":"463","article-title":"Survey on once-daily therapy with ceftriaxone for pediatric bacterial infections","volume":"55","author":"Iwata","year":"2007","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.04.006_bib19","first-page":"387","article-title":"Investigation on optimal regimen of ceftazidime against infection caused by Pseudomonas aeruginosa using Monte Carlo simulation]","volume":"60","author":"Mikamo","year":"2007","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2019.04.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19300984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19300984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:58:52Z","timestamp":1761159532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19300984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1341321X19300984"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.04.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic-pharmacodynamic comparison of ceftriaxone regimens in acute cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}